The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Updates on the use of zanubrutinib in WM patients intolerant to ibrutinib or acalabrutinib
Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly discusses the safety and efficacy of zanubrutinib in patients with Waldenström’s macroglobulinemia (WM) who are intolerant to ibrutinib or acalabrutinib. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
